Article
FDA Grants Fast Track Designation to Novel CAR T-Cell Therapy for B-Cell Malignancies
Rating:
0.0
Views:
79
Likes:
1
Library:
1
The FDA granted fast track designation to the novel “switchable” CAR-T cell therapy known as CLBR001 + SWI019 for the treatment of B-cell malignancies.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value